Anuj Malik, MD
Infectious Disease · Tulsa, OKNPI 1871766428
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.5%), education and food and beverage — rather than concentrated in one kind of arrangement. 4 manufacturers reported payments, led by ZOLL Medical Corporation at 59.5% of the total. Reporting peaked in 2021 at $258 and has fallen 81.9% since, to $47 in 2024. That places this record below the midpoint for infectious disease clinicians in OK, where the typical reported total is $448.
Across 7 payments — averaging $62.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Medical Corporation$258
- Novo Nordisk$129
- Ambu Inc.$25
- AbbVie$22
Across 91 payments — averaging $22,684 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$961K
- Rigel Pharmaceuticals, Inc.$872K
- Regeneron$231K
What the payments were for
- Consulting fees$25859%
- Food & beverage$4711%
- Education$12930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Medical Corporation | 1 | $258 |
| Novo Nordisk | 4 | $129 |
| Ambu Inc. | 1 | $25 |
| AbbVie | 1 | $22 |
How this compares
$434 in reported general payments places this provider in the 45th percentile of 51 infectious disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 13 | $13,030 |
| Topiramate | 40 | $205 |
| Doxycycline Hyclate | 16 | $139 |
| Prednisone | 16 | $40 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Tulsa
- Peter OkwuasabaTulsa$15K
- David ScheckTulsa$5K
- Heather BellTulsa$2K
- Sristi BhattaraiTulsa$2K
- Hosam MousselliTulsa$1K
- Stephan HambazTulsa$729
- Edemekong BasseyTulsa$688
- Yasir AhmedTulsa$448
- Ashley JenkinsTulsa$379
- Janice TeTulsa$114
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.